Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
103 participants
INTERVENTIONAL
2010-12-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
SGAD's are used for thyroid surgery, ear surgery, carotid endarterectomy, adenotonsillectomy and laser pharyngoplasty, which require a variety of head-neck positions. Changing the head and neck position leads to changes in the shape of the pharynx, which causes variation in the cuff pressure and oropharyngeal leak pressure. Oropharyngeal leak pressure values play a determining role in protecting the airway from high cuff pressure. Additionally it shows that the laryngeal mask is correctly placed and is a sign of the effectiveness of positive pressure ventilation. During surgery head-neck and trunk position may change. As a result there is a need for research evaluating the effect of head and neck position on oropharyngeal leak pressure during SGAD use.
AIM
The aim of this study is to compare the effect of different head and neck positions on the oropharyngeal leak pressure in LMA-Unique and I-Gel applications. Additionally the placement duration, ease and success of these two supraglottic airway devices will be compared.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Clinical Performance of Supraglottic Airway Devices
NCT06850675
Comparison of Efficacy of Two Supraglottic Airway Devices: I-gel and the Self-pressurized Air-q in Elderly Patients
NCT04365192
Comparison of Gastric Volume in I-gel and ProSeal Laryngeal Mask Airways
NCT07138092
Laryngeal Mask Supreme and I-Gel in Edentulate Geriatric Patients
NCT03760679
Clasic Laryngeal Mask Airway(C-LMA) and I-gel Releated Regurgitation and Complications
NCT01876836
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
All patients preoperatively evaluated and ASA and Mallampati classification recorded.
All SGAD's inserted by the same experienced researcher. After placement of laryngeal mask, to standardize postoperative pharyngeal morbidity, cuff pressure (cuff pressure manometer, Ruch, Germany) was monitored.
EXCLUSION CRITERIA:
* Any neck or upper respiratory pathology
* Those at risk of gastric content regurgitation/aspiration (previous upper Gastro-intestinal surgery, known hiatus hernia, Gastroesophageal reflux, history of peptic ulcer, full stomach, pregnancy)
* Possibility of and those with history of difficult intubation (history of impossible intubation, Mallampati classification 3-4, sterno mental distance less than 12 cm, thyromental distance less than 6 cm, head extension less than 90 degrees, mouth opening less than 1.5 cm)
* Those with low pulmonary compliance or high airway resistance (morbid obesity, lung disease)
* Throat pain, dysphagia and dysphonia
* Patients with cervical disc hernia
Patients taken to the operating room were given standard monitoring before anesthesia induction. Patients were preoxygenated with 6 L/min oxygen for 3 minutes through a face mask.
Anesthesia induction was provided by 0.02 mg/kg midazolam, 1-2 mcg/kg fentanyl, 1.5-2 mg/kg propofol and 0.5 mg/kg rocuronium.
All patients have neuromuscular junction monitoring (TOF-GUARD, Biometer International A.S. DENMARK) and when TOF is zero SGAD was inserted with the standard method according to the firm's recommendations.
During SGAD placement, if necessary additional dose of 0.5 mg/kg propofol was given depending on patient reaction. During this procedure cases were ventilated with 100% oxygen though a mask.
STUDY GROUPS:
Group U (UNIQUE): LMA- UNIQUE, inserted according to described standard method
Group I (I-GEL ) : I-GEL, inserted with standard technique according to users manual
For LMA-U the laryngeal mask cuff was inflated so that cuff pressure is less than 60 cm H2O with leak preventive volume. After the operation before the laryngeal mask was removed the cuff pressure was measured again and recorded.
To check SGAD placement bilateral chest movement was observed and capnography be used to confirm a square wave shape. After SGAD was placed oropharyngeal leak test was completed. Oropharyngeal leak pressure were tested in both groups first in neutral head position, then at maximum extension and with head at maximum rotation to the right. In every position the leak measurement was made 60 seconds after position is changed. In order to prevent the SGAD from being seen by the researcher during the tests the patient's head was covered.
Oropharyngeal leak pressure was measured with the ring system expiratory valve closed and 4 L/min flow. To prevent exposure of the lungs to barotrauma, when peak airway pressure reaches 40 cm H2O the expiratory valve was opened .
Leak pressure was evaluated in two ways;
1. The stethoscope is placed above the patient's left thyroid part of the trachea and the sound of a leak is listened for
2. Checked when the aneroid manometer is held steady (manometer stability test)
When the sound of the leak is heard, the pressure on the manometer were recorded separately in both situations.
Anesthesia was maintained with 5% O2/air mix with 1.5-2.5% sevoflurane. Systolic arterial pressure (SAP), diastolic arterial pressure (DAP), mean arterial pressure (MAP), and heart rate (HR) values were measured and recorded immediately before anesthesia induction, immediately before airway device placement and at 1, 2, and 3 minutes after airway placement is checked. The time for successful placement (duration from mouth opening to first successful ventilation), number of attempts, and ease of placement were recorded.
Ease of insertion:
1. no reaction
2. straining, retching
3. alternative airway management
The Mallampati score, type of supraglottic airway device, type of operation and total duration of anesthesia were recorded. Any problems occurring during head and neck positions was noted.
The cuff pressure was measured after surgery while the patient is still in deep anesthesia.
When the patient is conscious the SGAD was removed and the duration of use was recorded (time from insertion to removal).
After the SGAD is removed the presence of blood was evaluated
1. no blood
2. trace amounts of blood
3. definite amount of blood
The patients throat pain, voice loss and difficulty swallowing were evaluated when leaving the recovery room and by telephone 24 hours later by a researcher blind to the insertion technique. To evaluate throat pain the VAS 10 (verbal analogue scale) was used
EXPULSION CRITERIA:
* Oxygen saturation by pulse oximetry values falling by 90% during airway insertion
* Cases developing laryngospasm
* Cases with incomplete records
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group U (UNIQUE)
Group LMA- UNIQUE, inserted according to described standard method. Between 30-40 kg, no.3. Between 50-70 kg, no. 4 Between 70-100 kg, no. 5. LMA-Unique Before SGAD is inserted, a water-based lubricant without local anesthetic, was spread on the surfaces that will touch the palate and LMA-U cuff was completely deflated.oup U (UNIQUE): Group Laryngeal Mask Airway-Unique.
Group U (UNIQUE)
Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
Group I (I-GEL ): Group I-GEL
Group I (I-GEL): Between 30-60 kg, no. 3. Between 50-90 kg, no. 4. For \> 90 kg no.5. I-GEL
I-GEL
Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.
I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Group U (UNIQUE)
Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
I-GEL
Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.
I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18-65 years
Exclusion Criteria
* Those at risk of gastric content regurgitation/aspiration (previous upper gastro-intestina system surgery, known hiatus hernia, gastroesophageal reflux, history of peptic ulcer, full stomach, pregnancy)
* Possibility of and those with history of difficult intubation (history of impossible intubation, Mallampati classification 3-4, sterno mental distance less than 12 cm, thyromental distance less than 6 cm, head extension less than 90 degrees, mouth opening less than 1.5 cm)
* Those with low pulmonary compliance or high airway resistance (morbid obesity, lung disease)
* Throat pain, dysphagia and dysphonia
* Patients with cervical disc hernia
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dokuz Eylul University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sule Ozbilgin
Anaesthesiology and Reanimation
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
FARUK ÖZATA, M.D.
Role: PRINCIPAL_INVESTIGATOR
STUDY DESİGN
BAHAR KUVAKİ, M.D.
Role: STUDY_DIRECTOR
Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Dokuz Eylül University, School of Medicine, Department of Anesthesiology and Reanimation
Izmir, Narlıdere, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
10-11.1/30
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.